[Gastrointestinal stromal tumors: evolution of a tumor concept from unclassifiable neoplasms to targeted molecular...

Area of Science:

• Oncology
• Molecular Diagnostics
• Gastrointestinal Pathology

Background:

• Activating mutations in C-KIT and PDGFRA oncogenes drive gastrointestinal stromal tumors (GIST).
• Tyrosine kinase inhibitors (TKIs) like Imatinib and Sunitinib have revolutionized GIST treatment.
• Accurate histopathological diagnosis and risk stratification are essential for GIST management.

Purpose of the Study:

• To review current advancements in GIST histopathological and molecular diagnostics.
• To highlight the significance of kinase mutation analysis in optimizing patient treatment strategies.
• To discuss the role of mutation type and location in guiding drug selection and predicting TKI resistance.

Main Methods:

• Review of current literature on GIST diagnostics and targeted therapy.
• Analysis of the impact of C-KIT and PDGFRA mutations on GIST behavior.
• Correlation of mutation profiles with TKI response and resistance patterns.

Main Results:

• Specific C-KIT and PDGFRA mutations are key targets for TKI therapy in GIST.
• Mutation analysis informs drug selection, dosage, and prognosis.
• Understanding mutation patterns aids in predicting and managing secondary resistance to TKIs.

Conclusions:

• Precise molecular diagnostics, particularly kinase mutation analysis, are fundamental for personalized GIST treatment.
• Histopathological and molecular assessments are integral for effective risk stratification and therapeutic planning.
• Ongoing research in GIST diagnostics aims to further optimize patient care and outcomes.